Browse News
Filter News
Found 757,483 articles
-
Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis.
-
Magenta Therapeutics is searching for viable business options after a patient's death halted a Phase I/II trial in acute myeloid leukemia.
-
Keytruda could be on its way to snagging another indication as a first-line therapy for endometrial cancer after the company announced positive Phase III results Friday.
-
Structure Therapeutics expects to bring in $161.1 million from an upsized IPO, announced Friday.
-
Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.
-
TRYAL, Inc. enters the market with sights set on innovating the eClinical industry
2/3/2023
February 3, 2023, Austin, Texas. TRYAL, an eClinical software platform company officially announced their launch today with $6 million in funding and technology designed to revolutionize the clinical trials technology landscape.
-
KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029
2/3/2023
Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights:
-
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
2/3/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2022 and provided a business update.
-
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma
2/3/2023
Merck today announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.
-
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
2/3/2023
BD (Becton, Dickinson and Company) today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.
-
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
2/3/2023
Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.
-
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
2/3/2023
SPR Therapeutics announced it has obtained clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling, which increases the intended patient population of the SPRINT® PNS System, along with new advances to enhance and simplify the SPRINT PNS System’s lead securement mechanism.
-
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
2/3/2023
Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug application (IND) for AC0676 for the treatment of patients with relapsed/refractory B-cell malignancies.
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
2/3/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.
-
The FLOW-AF multicenter, randomized controlled trial shows Ablacon's Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation
2/3/2023
Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation (AF), announced today the 12-month results from the FLOW-AF trial (NCT04473963).
-
Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer
2/3/2023
Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology.
-
Genetic Technologies Announces $5 Million Registered Direct Offering
2/3/2023
Genetic Technologies Limited today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale in a registered direct offering of 3,846,155 American Depositary Shares.
-
Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis
2/3/2023
Neurent Medical today announced its NEUROMARK ® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.
-
Bruker Announces Successful Customer Installations of First Two Compact 1.0 GHz NMR Systems to Advance Structural Biology
2/3/2023
Bruker today announced successful customer installations of two novel, compact 1.0 GHz NMR spectrometers for advanced structural and molecular biology applications well ahead of original schedules in late 2022.
-
PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners
2/3/2023
PaxMedica, Inc. today announced that the Company has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP.